Filing Details

Accession Number:
0001735276-22-000069
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-17 16:07:02
Reporting Period:
2022-08-15
Accepted Time:
2022-08-17 16:07:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1178670 Alnylam Pharmaceuticals Inc. ALNY Pharmaceutical Preparations (2834) 770602661
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1226295 A Phillip Sharp 675 West Kendall Street
Henri A. Termeer Square
Cambridge MA 02142
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-15 30,000 $30.09 30,000 No 4 M Direct
Common Stock Acquisiton 2022-08-15 3,670 $63.86 33,670 No 4 M Direct
Common Stock Disposition 2022-08-15 98 $226.16 33,572 No 4 S Direct
Common Stock Disposition 2022-08-15 1,218 $228.33 32,354 No 4 S Direct
Common Stock Disposition 2022-08-15 11,600 $229.93 20,754 No 4 S Direct
Common Stock Disposition 2022-08-15 16,186 $230.71 4,568 No 4 S Direct
Common Stock Disposition 2022-08-15 3,853 $231.65 715 No 4 S Direct
Common Stock Disposition 2022-08-15 715 $232.81 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2022-08-15 3,670 $0.00 3,670 $63.86
Common Stock Stock Option (right to buy) Disposition 2022-08-15 30,000 $0.00 30,000 $30.09
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2024-01-02 No 4 M Direct
0 2014-06-06 2023-06-06 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 266,899 Indirect by Trust
Footnotes
  1. The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2022.
  2. Sale prices ranged from $228.00 to $228.80.
  3. Sale prices ranged from $229.29 to $230.29.
  4. Sale prices ranged from $230.30 to $231.30.
  5. Sale prices ranged from $231.31 to $232.26.
  6. Sale prices ranged from $232.53 to $233.16.
  7. Includes shares held by the Phillip A. Sharp Revocable Trust, of which the reporting person and his spouse are co-trustees. Also includes shares held in trust for the benefit of the reporting persons children, of which the reporting persons children and spouse are the trustees.
  8. The stock option was fully vested as of 12/31/14.